- Oligonucleotides, short DNA or RNA sequences, are fundamental building blocks in life sciences, vital for applications across genomics research, diagnostics, and therapeutic development. Their increasing precision and versatility are positioning them as indispensable tools in modern biotechnology
- The escalating demand for oligonucleotide synthesis is primarily fueled by the burgeoning field of personalized medicine, growing investments in life science R&D, and the widespread adoption of advanced technologies such as Next-Generation Sequencing (NGS) and CRISPR gene editing. The robust pipeline of oligonucleotide-based drugs also plays a significant role in market expansion
- North America dominates the oligonucleotide synthesis market with the largest revenue share of 40.7% in 2024, characterized by its well-established biotechnology and pharmaceutical industries, substantial R&D spending, and early adoption of cutting-edge biotechnologies. The region benefits from a strong presence of key industry players and significant investments in genomics and precision medicine initiatives
- Asia-Pacific is expected to be the fastest growing region in the oligonucleotide synthesis market during the forecast period due to increasing biotech investments, growing academic research, rising healthcare expenditure, and supportive government policies aimed at enhancing genomics and precision medicine
- Therapeutic Applications segment dominates the oligonucleotide synthesis market with a market share of 42.7% in 2024, driven by the increasing number of regulatory approvals for oligonucleotide-based drugs for various neurological and rare diseases, along with a growing focus on personalized medicine and the potential of these drugs to treat previously untreatable conditions
